Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $13.13

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $13.13.

A number of research analysts have recently commented on CMPX shares. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Jefferies Financial Group raised their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, February 10th. HC Wainwright restated a "buy" rating and issued a $24.00 target price on shares of Compass Therapeutics in a research report on Monday, April 21st. Wedbush reiterated an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday, April 1st. Finally, Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective on the stock.

Compass Therapeutics Trading Down 0.5%

Compass Therapeutics stock traded down $0.01 during midday trading on Thursday, reaching $2.09. 529,883 shares of the stock traded hands, compared to its average volume of 920,626. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The firm has a market cap of $289.01 million, a price-to-earnings ratio of -5.65 and a beta of 1.40. The firm has a fifty day moving average price of $1.91 and a two-hundred day moving average price of $2.12.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). Analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current year.

Insider Buying and Selling at Compass Therapeutics

In related news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Anderman acquired 20,000 shares of the business's stock in a transaction on Monday, April 7th. The shares were bought at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the acquisition, the insider now owns 21,000 shares in the company, valued at approximately $32,340. This trade represents a 2,000.00% increase in their position. The disclosure for this purchase can be found here. 29.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently made changes to their positions in CMPX. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new position in Compass Therapeutics in the 4th quarter valued at approximately $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics in the 4th quarter worth approximately $27,000. Mariner LLC acquired a new stake in Compass Therapeutics during the fourth quarter valued at $30,000. Finally, Squarepoint Ops LLC bought a new stake in Compass Therapeutics in the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.